Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001140361-19-01274 0001780408 XXXXXXXX LIVE 5 Common Stock, par value $0.001 per share 03/05/2025 false 0001743881 10806X102 BridgeBio Pharma, Inc. 3160 Porter Drive Suite 250 Palo Alto CA 94304 Christopher Lee, Esq. 212-750-8300 Kohlberg Kravis Roberts & Co. L.P. 30 Hudson Yards New York NY 10001 0001780408 KKR Genetic Disorder L.P. OO DE 19260971 0 19260971 0 19260971 N 10.1 PN Y KKR Genetic Disorder GP LLC OO DE 19260971 0 19260971 0 19260971 N 10.1 OO Y KKR Group Partnership L.P. OO E9 19260971 0 19260971 0 19260971 N 10.1 PN Y KKR Group Holdings Corp. OO DE 19260971 0 19260971 0 19260971 N 10.1 CO Y KKR Group Co. Inc. OO DE 19260971 0 19260971 0 19260971 N 10.1 CO Y KKR & Co. Inc. OO DE 19260971 0 19260971 0 19260971 N 10.1 CO Y KKR Management LLP OO DE 19260971 0 19260971 0 19260971 N 10.1 PN Y Henry R. Kravis OO X1 0 19260971 0 19260971 19260971 N 10.1 IN Y George R. Roberts OO X1 0 19260971 0 19260971 19260971 N 10.1 IN Common Stock, par value $0.001 per share BridgeBio Pharma, Inc. 3160 Porter Drive Suite 250 Palo Alto CA 94304 This Amendment No. 5 ("Amendment No. 5") to Schedule 13D relates to the common stock, par value $0.001 per share (the "Common Stock"), of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"), and amends the initial statement on Schedule 13D filed on July 10, 2019, as amended by Amendment No. 1 to Schedule 13D filed on June 1, 2020, Amendment No. 2 to Schedule 13D filed on October 6, 2020, Amendment No. 3 to Schedule 13D filed on February 17, 2021 and Amendment No. 4 to Schedule 13D filed on September 17, 2024 (as so amended, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported in the Schedule 13D. Unless otherwise indicated herein, capitalized terms used but not defined in this Amendment No. 5 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 5(c) below is incorporated by reference herein. Items 5(a)-(c) of the Schedule 13D are hereby amended and restated as follows: The information set forth in Items 2 and 3 and the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. KKR Genetic Disorder L.P. holds 19,260,971 shares of Common Stock representing approximately 10.1% of the outstanding shares of Common Stock, based on 190,188,626 shares of Common Stock outstanding as of February 13, 2025, as reported in the Issuer's Form 10-K filed with the Securities and Exchange Commission on February 20, 2025. Each of KKR Genetic Disorder GP LLC (as the general partner of KKR Genetic Disorder L.P.), KKR Group Partnership L.P. (as the sole member of KKR Genetic Disorder GP LLC), KKR Group Holdings Corp. (as the general partner of KKR Group Partnership L.P.), KKR Group Co. Inc. (as the sole shareholder of KKR Group Holdings Corp.), KKR & Co. Inc. (as the sole shareholder of KKR Group Co. Inc.), KKR Management LLP (as the Series I preferred stockholder of KKR & Co. Inc.) and Messrs. Henry R. Kravis and George R. Roberts (as the founding partners of KKR Management LLP) may be deemed to be the beneficial owner of the securities held directly by KKR Genetic Disorder L.P., in each case, as described more fully in this Schedule 13D. The filing of this Schedule 13D shall not be construed as an admission that any of the above-listed entities or individuals is the beneficial owner of any securities covered by this Schedule 13D. To the best knowledge of the Reporting Persons, none of the individuals named in Item 2 beneficially owns any shares of Common Stock except as described herein. See Item 5(a) above. On March 5, 2025, KKR Genetic Disorder L.P. sold 6,000,000 shares of Common Stock in a block sale at a price of $32.96 per share pursuant to Rule 144 under the Securities Act of 1933, as amended (the "March 2025 Sale"). Except as otherwise described in this Schedule 13D, none of the Reporting Persons, or, to the best knowledge of the Reporting Persons, any other individual named in Item 2 has engaged in any transaction in any shares of Common Stock during the past 60 days. Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit I - Joint Filing Agreement, dated as of September 17, 2024, by and among the Reporting Persons (incorporated by reference to Exhibit I to Schedule 13D filed with the Securities and Exchange Commission by the Reporting Persons on September 17, 2024). KKR Genetic Disorder L.P. /s/ Christopher Lee Christopher Lee, Assistant Secretary, KKR Genetic Disorder GP LLC, its general partner 03/07/2025 KKR Genetic Disorder GP LLC /s/ Christopher Lee Christopher Lee, Assistant Secretary 03/07/2025 KKR Group Partnership L.P. /s/ Christopher Lee Christopher Lee, Secretary, KKR Group Holdings Corp., its general partner 03/07/2025 KKR Group Holdings Corp. /s/ Christopher Lee Christopher Lee, Secretary 03/07/2025 KKR Group Co. Inc. /s/ Christopher Lee Christopher Lee, Secretary 03/07/2025 KKR & Co. Inc. /s/ Christopher Lee Christopher Lee, Secretary 03/07/2025 KKR Management LLP /s/ Christopher Lee Christopher Lee, Assistant Secretary 03/07/2025 Henry R. Kravis /s/ Christopher Lee Christopher Lee, Attorney-in-fact 03/07/2025 George R. Roberts /s/ Christopher Lee Christopher Lee, Attorney-in-fact 03/07/2025